Personalized dosing of ocrelizumab in MS
What was tested
Treatment tested
- Ocrelizumab
B-lymphocyte antigen CD20 binding agent
What it measured
Main measures
The two co-primary end points are the difference of percentage of confirmed relapse-free patients between the two treatment groups after 96 weeks follow-up and the difference of percentage of patients without new/enlarging T2 MRI lesions between the two treatment groups after 96 weeks follow-up.
RelapsesMRI lesions
Other measures (1)
• Number of total relapses and annualized relapse rate calculated as the total number of relapses per patient divided by years of follow-up.
Relapses
Loading reviews and guidelines…
Related trials
- Operetta III
Phase 2 · Not yet recruiting
Still running
- SOLI
Recruiting
Still running
- SONATA-MS
Recruiting
Still running
- HiHat
Phase 2 · Recruiting
Still running
- REDIFINE MS
Recruiting
Still running
- TG1101-RMS-PED304
Phase 2 / Phase 3 · Recruiting
Still running
History
- In scope changed from true to false
Started
Mar 2022
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error